NASDAQ$XNCR
Xencor Inc · Q3 2023 earnings
Q3 2023 earnings · · Investor relations
Briefing
Announced measures to strengthen balance sheet and maximize focus on promising programs. Sold a portion of Ultomiris® and Monjuvi® royalties, generating $215 million upfront.
Xencor reported third-quarter financial results, highlighting a $215 million upfront payment from a royalty transaction with OMERS Life Sciences. The company is focusing on targeted T cell-engaging bispecifics and has made pipeline decisions to extend its cash runway into 2027.
- Received $215 million through royalty transaction with OMERS Life Sciences for portions of Ultomiris® and Monjuvi® royalties.
- Stopped internal development of XmAb104 due to emerging data from Phase 1 expansion cohorts not meeting efficacy criteria.
- Exercised right under the Genentech agreement to convert co-development of efbalropendekin alfa into a milestone and royalty arrangement without cost-sharing.
- Plans to submit an investigational new drug (IND) application for XmAb541 by year end.
Headline financials
Revenue & EPS history
Xencor · Revenue · Quarterly
$59.2M
Forward guidance
Xencor expects to have cash to fund research and development programs and operations into 2027. The Company expects to end 2023 with between $615 million and $665 million in cash, cash equivalents and marketable debt securities.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q3 2023
-0.1%
Avg return
Earnings day
-1.1%
Avg return
5 days after
-0.1%
Avg return
30 days after
48%
25 / 52 earnings
Positive
+11.3%
Q2 2018
Best reaction
-16.6%
Q2 2019
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +1.2% | -0.5% | -8.4% | |
| Q4 2025 | +1.5% | +4.1% | -3.3% | |
| Q3 2025 | -2.4% | +3.5% | +20.4% | |
| Q1 2025 | +0.2% | -4.6% | +12.3% | |
| Q3 2024 | +7.7% | +8.3% | +17.8% | |
| Q2 2024 | -6.9% | -16.4% | -13.3% | |
| Q1 2024 | -5.0% | -13.9% | -8.1% | |
| Q4 2023 | -11.9% | -7.9% | -14.5% | |
| Q3 2023 | -6.3% | -7.3% | +9.8% | |
| Q2 2023 | +2.8% | +1.4% | -4.6% | |
| Q1 2023 | -2.2% | -2.4% | -1.6% | |
| Q4 2022 | -3.2% | -6.1% | -18.3% | |
| Q3 2022 | +8.6% | +9.0% | +9.9% | |
| Q2 2022 | +2.3% | +1.4% | -8.5% | |
| Q1 2022 | -1.0% | -2.5% | -16.7% | |
| Q4 2021 | +1.3% | -2.4% | -12.3% | |
| Q3 2021 | -7.0% | -6.4% | -13.3% | |
| Q2 2021 | +2.9% | -2.3% | +7.8% | |
| Q1 2021 | -2.4% | -6.3% | -10.4% | |
| Q4 2020 | -1.3% | +0.3% | -10.8% | |
| Q3 2020 | -8.7% | -3.9% | -5.7% | |
| Q2 2020 | -3.2% | +1.0% | +6.6% | |
| Q1 2020 | +7.1% | +7.3% | -3.2% | |
| Q4 2019 | -8.8% | -7.6% | -18.2% | |
| Q3 2019 | -1.0% | -1.0% | +20.9% | |
| Q2 2019 | -16.6% | -15.6% | -18.9% | |
| Q1 2019 | +10.7% | +4.9% | -3.5% | |
| Q4 2018 | -3.1% | -0.8% | +1.3% | |
| Q3 2018 | +6.2% | -0.3% | +3.7% | |
| Q2 2018 | +11.3% | +10.0% | +10.1% | |
| Q1 2018 | -2.5% | +4.4% | +38.4% | |
| Q4 2017 | +4.8% | +0.9% | +2.6% | |
| Q3 2017 | +2.1% | +4.6% | +10.7% | |
| Q2 2017 | +4.7% | -3.9% | -1.9% | |
| Q1 2017 | -6.8% | -6.3% | -12.0% | |
| Q4 2016 | +7.6% | +5.5% | -5.6% | |
| Q3 2016 | -11.0% | -4.7% | +24.9% | |
| Q2 2016 | +9.4% | +16.0% | +10.7% | |
| Q1 2016 | -2.9% | — | — | |
| Q4 2015 | +11.2% | — | — | |
| Q3 2015 | +4.6% | — | — | |
| Q2 2015 | -2.2% | — | — | |
| Q1 2015 | -5.5% | — | — | |
| Q4 2012 | +1.8% | — | — | |
| Q4 2014 | -0.9% | — | — | |
| Q3 2014 | +3.6% | — | — | |
| Q3 2013 | +3.6% | — | — | |
| Q2 2013 | +1.7% | — | — | |
| Q2 2014 | +2.6% | — | — | |
| Q4 2013 | -1.6% | — | — | |
| Q1 2013 | -1.6% | — | — | |
| Q1 2014 | -2.3% | — | — | |
| Q3 2012 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro